目的 探討脾氨肽口服液聯(lián)合依匹斯汀治療慢性蕁麻疹的臨床療效。方法 選取延安大學附屬醫(yī)院2016年5月-2017年5月收治的慢性蕁麻疹患者121例，隨機分成對照組（60例）和治療組（61例）。對照組患者口服鹽酸依匹斯汀片，2片/次，1次/d；治療組患者在對照組的基礎上口服脾氨肽口服液，10 mL/次，1次/d。兩組患者均連續(xù)治療4周。評價兩組患者臨床療效，同時比較治療前后兩組患者臨床癥狀積分、血清炎性指標和不良反應。結果 治療后，對照組的臨床總有效率為83.33%，顯著低于治療組的96.72%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者瘙癢、風團數(shù)量、風團大小癥狀積分均明顯降低（P<0.05）；且治療組患者癥狀積分降低的更明顯（P<0.05）。治療后，兩組患者白介素（IL）-4、IL-10和C反應蛋白（CRP）水平顯著性降低（P<0.05）；且治療組患者各指標均明顯低于對照組（P<0.05）。治療期間，治療組患者不良反應發(fā)生率為6.56%，明顯低于對照組患者的21.67%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 脾氨肽口服液聯(lián)合依匹斯汀治療慢性蕁麻疹臨床療效顯著，同時能夠顯著改善炎性反應，具有一定的臨床推廣應用價值。

Objective To explore the clinical efficacy of Spleen Aminopeptide Oral Solution combined with epinastine in treatment of chronic urticaria. Methods Patients (121 cases) with chronic urticaria in Yan'an University Affiliated Hospital from May 2016 to May 2017 were randomly divided into control (60 cases) and treatment (61 cases) groups. Patients in the control group were po administered with Epinastine Hydrochloride Tablets, 2 tablets/time, once daily. Patients in the treatment group were po administered with Spleen Aminopeptide Oral Solution on the basis of the control group, 10 mL/time, once daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptom scores, serum inflammatory markers and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 83.33%, which was significantly lower than that (96.72%) in the treatment group, and the difference was statistically significant between two groups (P<0.01). After treatment, the symptom scores of pruritus, numbers and size of wheal in two groups were significantly decreased (P<0.05). And these scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the serum IL-4, IL-10 and CRP levels in two groups were significantly decreased (P<0.05). And these inflammatory markers in the treatment group were significantly lower than those in the control group (P<0.05). During the treatment, the incidence of adverse reaction in the treatment group was 6.56%, which were significantly lower than 21.67% in the control group, with significant difference between two groups (P<0.05). Conclusion Spleen Aminopeptide Oral Solution combined with epinastine has significant effect in treatment of chronic urticaria, which can significantly improve the inflammatory reaction, which has a certain clinical application value.